Alvotech and AbbVie Settle Patent Dispute
LexBlog IP
MARCH 10, 2022
The announcement states that under the settlement agreement, Alvotech has non-exclusive rights to market AVT02 in the United States starting July 1, 2023. ” The announcement further states that FDA has deferred action on Alvotech’s BLA until necessary inspections are completed.
Let's personalize your content